|
|
|
| home > white papers > Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models - DrugDev |
|
|
 WHITE PAPERS |
|
DrugDev
|
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
|
|
For the last 20 years, pharmaceutical companies have turned to a variety
of clinical outsourcing solutions to reduce costs and improve
timelines, enabling them to focus on their core value of research and
development. In today’s tightly competitive market, companies are
constantly striving for ways to further cut costs and reduce study
startup cycle times, while maintaining quality.
One of the key
cost factors in global R&D spending, estimated at around $102
billion per Kalorama market research, is the cost of conducting clinical
trials. CRO’s, which account for about 30% of the total R&D
spending, have risen to the challenge of the clinical, technical and
administrative management of these trials. But some pharmaceutical
companies question how much control to relinquish to vendor partners,
especially in the legal arena, due to potential ramifications.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer
BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >> |
|
 |
White Papers |
 |
|
Contemporary Issues in Comparator Trial Supply
Clinigen CTS
As trial design and execution becomes ever-more complex, initiatives to
adapt, increase efficiency and control costs without compromising
quality become paramount. Here, Clinigen CTS covers the broad issues and
summarises the responses our industry is making in this increasingly
demanding landscape.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
|
.jpg)
